KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Charles River Laboratories International (CRL) EBT (2016 - 2025)

Charles River Laboratories International (CRL) has 17 years of EBT data on record, last reported at -$294.1 million in Q4 2025.

  • For Q4 2025, EBT fell 35.66% year-over-year to -$294.1 million; the TTM value through Dec 2025 reached -$99.5 million, down 206.86%, while the annual FY2025 figure was -$99.5 million, 206.86% down from the prior year.
  • EBT reached -$294.1 million in Q4 2025 per CRL's latest filing, down from $87.2 million in the prior quarter.
  • Across five years, EBT topped out at $244.9 million in Q4 2022 and bottomed at -$294.1 million in Q4 2025.
  • Average EBT over 5 years is $83.9 million, with a median of $116.3 million recorded in 2023.
  • Peak YoY movement for EBT: soared 67.18% in 2022, then plummeted 203.87% in 2024.
  • A 5-year view of EBT shows it stood at $163.6 million in 2021, then skyrocketed by 49.67% to $244.9 million in 2022, then decreased by 14.79% to $208.7 million in 2023, then tumbled by 203.87% to -$216.8 million in 2024, then plummeted by 35.66% to -$294.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were -$294.1 million in Q4 2025, $87.2 million in Q3 2025, and $71.4 million in Q2 2025.